Even More Funding Raises: #SolsticeOncology $225M Series A; #Euclyd €200M ($230M) Series A; #Factory $200M Series D
Mergers: #Everbank reverse merger with #WaFdBank; #MayMobility & #ACPHoldingsAcquisitionCorp. (SPAC);
#TamarackValleyEnergy & #HeadwaterExploration
Mergers: #Everbank reverse merger with #WaFdBank; #MayMobility & #ACPHoldingsAcquisitionCorp. (SPAC);
#TamarackValleyEnergy & #HeadwaterExploration
September 18, 2026 at 7:07 PM
Even More Funding Raises: #SolsticeOncology $225M Series A; #Euclyd €200M ($230M) Series A; #Factory $200M Series D
Mergers: #Everbank reverse merger with #WaFdBank; #MayMobility & #ACPHoldingsAcquisitionCorp. (SPAC);
#TamarackValleyEnergy & #HeadwaterExploration
Mergers: #Everbank reverse merger with #WaFdBank; #MayMobility & #ACPHoldingsAcquisitionCorp. (SPAC);
#TamarackValleyEnergy & #HeadwaterExploration
#pharmalicensingdeals #pharmaceuticalassets #VirBiotech #Vir #HarbourBioMed #UnnaturalProducts #Genhouse #CSL #Astellas #SolsticeOncology #antiCTLA4antibody #Novartis #UnnaturalProducts #macrocyclicpeptidedrugs #GileadSciences #syntheticlethality #GenhouseBio #Arcellx #EliLilly
zurl.co/HOdjt
zurl.co/HOdjt
Astellas bets on Vir cancer drug, and other licensing deals
Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.
zurl.co
February 25, 2026 at 12:05 PM